WallStSmart

Flex Ltd (FLEX)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Flex Ltd generates 61% more annual revenue ($26.83B vs $16.63B). IQV leads profitability with a 8.3% profit margin vs 3.2%. IQV appears more attractively valued with a PEG of 0.72. IQV earns a higher WallStSmart Score of 66/100 (B-).

FLEX

Buy

60

out of 100

Grade: C

Growth: 6.0Profit: 6.0Value: 5.3Quality: 6.0
Piotroski: 6/9Altman Z: 2.31

IQV

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 8.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FLEXUndervalued (+3.5%)

Margin of Safety

+3.5%

Fair Value

$67.21

Current Price

$145.07

$77.86 discount

UndervaluedFair: $67.21Overvalued
IQVUndervalued (+31.6%)

Margin of Safety

+31.6%

Fair Value

$259.19

Current Price

$173.55

$85.64 discount

UndervaluedFair: $259.19Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FLEX3 strengths · Avg: 8.3/10
Market CapQuality
$53.34B9/10

Large-cap with strong market position

PEG RatioValuation
0.948/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.9%8/10

16.9% revenue growth

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

PEG RatioValuation
0.728/10

Growing faster than its price suggests

Areas to Watch

FLEX4 concerns · Avg: 3.0/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

Debt/EquityHealth
1.093/10

Elevated debt levels

P/E RatioValuation
62.0x2/10

Premium valuation, high expectations priced in

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : FLEX

The strongest argument for FLEX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 16.9% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.

Bear Case : FLEX

The primary concerns for FLEX are Price/Book, Profit Margin, Debt/Equity. A P/E of 62.0x leaves little room for execution misses. Thin 3.2% margins leave little buffer for downturns.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Key Dynamics to Monitor

FLEX profiles as a growth stock while IQV is a value play — different risk/reward profiles.

FLEX carries more volatility with a beta of 1.45 — expect wider price swings.

FLEX is growing revenue faster at 16.9% — sustainability is the question.

IQV generates stronger free cash flow (491M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (66/100 vs 60/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Flex Ltd

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Flex Ltd. provides design, engineering, manufacturing and supply chain services and solutions to OEMs in Asia, the Americas and Europe. The company is headquartered in Singapore.

Visit Website →

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?